Subcutaneous Biologic Drugs and Affiliated Technologies Market is projected to be worth over USD 180

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, auto injectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
Subcutaneous Biologic Drugs and Affiliated Technologies Market, Trends by 2030
Market Segment:
Phase of development
• Approved
• Pre-registration & Phase III
• Phase II & Phase II/III
Type of molecule
• Cell and gene therapies
• Monoclonal antibodies
• Proteins
• Peptides (recombinant)
• Vaccines
• Others
Target therapeutic area
• Autoimmune disorders
• Blood disorders
• Bone disorders
• Genetic disorders
• Metabolic disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Others
Type of drug delivery system
• Large volume wearable injectors
• Autoinjectors
• Prefilled syringes
• Needle-free injectors
• Drug reconstitution systems
• Revenues from licensing deals
• Upfront payments
• Milestone payments
Key geographical regions
• North America
• Europe
• Asia Pacific
• Rest of the World
Request for PDF Sample:

Leave a Reply

Your email address will not be published. Required fields are marked *